Related Experiment Video
Updated: Jul 12, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma
Soji Toda1, Yukihiko Hiroshima2,3, Hiroyuki Iwasaki1
1Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
JCO Precision Oncology
|July 10, 2026
Summary
Genomic alterations in advanced papillary thyroid cancer (PTC) were analyzed. Mutations in the PI3K or cell cycle pathways are linked to poor prognosis in advanced PTC patients.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Papillary thyroid carcinoma (PTC) typically has a favorable prognosis.
- Limited knowledge exists on genomic alterations in advanced PTC and their prognostic impact.
- Mitogen-activated protein kinase (MAPK) pathway alterations initiate most thyroid cancers.
Purpose of the Study:
- To investigate gene alterations and their prognostic impact in advanced PTC.
- To clarify the frequency, co-occurrence, and exclusivity of gene alterations in advanced PTC.
- To identify potential therapeutic targets for advanced PTC.
Main Methods:
- Real-world database study utilizing nationwide clinical data and comprehensive genomic profiling (CGP) results.
- Analysis of 322 patients with advanced PTC who underwent CGP testing.
- Survival analysis to determine the impact of specific gene alterations on prognosis.
Main Results:
- The MAPK pathway showed the highest frequency of alterations (96%).
- Common mutations included TERT promoter and BRAF.
- Alterations in PTEN and CDKN2A were independent poor prognostic factors.
- Patients with PI3K or cell cycle pathway alterations had significantly shorter overall survival.
Conclusions:
- Gene alteration patterns in advanced PTC were elucidated.
- PI3K and cell cycle pathway alterations are associated with poor prognosis in advanced PTC.
- Targeting PI3K or cell cycle pathways may be a promising therapeutic strategy.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...